News Related to Bispecific Antibody-Drug Conjugates

Related coverage linked through entity extraction aliases.

TuHURA gains FDA orphan drug designation for IFx-2.0 in cutaneous melanoma

May 17, 2026

TuHURA Biosciences said the FDA granted orphan drug designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma based on Phase 1 data. The company said its Phase 3 IFx-2.0 study in first-line Merkel cell carcinoma continues to enroll.

Junshi Biosciences Reports 28% Revenue Growth in 2025; Absci Schedules Q4 Results

Mar 13, 2026

Junshi Biosciences reported total revenue of approximately RMB2,498 million in 2025, a 28% increase year-over-year, driven by toripalimab sales growth. Absci Corporation announced it will report fourth quarter and full year 2025 financial results on March 24, 2026.